Tian'an Pharmaceutical Co., Ltd.
TNPH · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -0.05% | -0.03% | -0.00% | -0.00% |
| EV / EBITDA | 389.31 | -1,350.97 | -1,786.81 | -875.73 |
| Quality | ||||
| ROIC | 25.88% | 8.15% | 8.08% | 17.79% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.19 | 0.35 | 0.02 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 145.13% | 166.33% | 521,215.70% |
| Free Cash Flow Growth | -75.89% | -2,388.89% | 0.00% | -100.84% |
| Safety | ||||
| Net Debt / EBITDA | 5.69 | -17.22 | -17.97 | -8.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |